Quick search:
Content Search
Result Content Research
Result Content Research
1 Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company
2 Financings for July 28, 2021 | 2021-07-28
3 Idorsia holds its Annual General Meeting of Shareholders
4 Economist says employment will continue to pick-up because ‘the jobs are out there’
5 FDA accepts the new drug application for review of Idorsia's daridorexant for the treatment of adult
6 Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022
7 After split from Actelion, Idorsia CEO plans to raise more cash in 2019
8 Press Release : European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
9 US FDA approves Ponvory (ponesimod) to treat adults with
10 The European Medicines Agency's CHMP issues a positive opinion recommending marketing authorisation for Ponvory
11 Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified
12 Idorsia establishes US commercial operations and leadership team
13 Primary School Gartenhof / BUR Architekten Primary School Gartenhof / BUR Architekten
14 Priothera closes $35M series A round for pivotal trial to boost HSCT outcomes in AML
15 Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
16 Exclusive: Fives Cryomec receives certification | News | gasworld
17 European Commission approves Ponvory (ponesimod) for the
18 Health: Idorsia to trial self-injection drug for heart attack victims
19 EMA gives green light to Actelion's Uptravi after safety review
20 J&J seals $30bn Actelion deal
21 Johnson & Johnson approaches Actelion about takeover deal
22 Actelion sees Uptravi price of $160,000-170,000/patient
23 A Holistic Multi Evidence Approach to Study the Fragmentation Behaviour of Crystalline Mannitol | Scientific Reports
24 Privacy Policy